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Parvovirus B19 (B19), currently the only accepted member of the Erythrovirus genus, is the only parvovirus known to be
pathogenic in humans. Recently a viral sequence, tentatively termed V9 which showed 11% variability from the published B19
sequences, was described from a patient with aplastic crisis. To search for additional parvovirus variants, we used the new
NS1/7.5EC PCR assay whose primers were designed from a conserved region of the B19/V9 sequence and encompasses anMfeI
restriction enzyme site that would allow differentiation between B19- and V9-like sequences. Screening of 225 serum and bone
marrow samples and 62 plasma pools identified one new atypical parvovirus sequence, A6, from an anemic HIV-positive patient.
A6 exhibited 88% similarity to B19 and 92% to V9, compared to 98% correspondence between reported B19 isolates. Based on
the genome similarity to B19, an RT-PCR for A6 capsid transcripts was developed and used to test for A6 infectivity of UT7/Epo/S1
cells. Despite high viral titers, A6 viral transcripts were not detected. Thus, although the prevalence of B19 variants probably is low,INTRODUCTION
Parvovirus B19 (B19) is currently the only accepted
member of the Erythrovirus genus and the only human
pathogenic parvovirus. The virus is the etiological agent
of erythema infectiosum and transient aplastic crisis
(TAC) and causes chronic anemia in immunocompro-
mised patients (Brown et al., 1994). Diagnosis of B19 is
by serology or viral DNA detection: the viral genome is
well conserved with only 2% sequence variability be-
tween isolates (Erdman et al., 1996; Nguyen et al., 1999).
The virus is not inactivated by standard heat or detergent
treatments and can be transmitted in blood and blood
products, prompting the development of nucleic acid
testing (NAT assays) for detection (Roth and Seifried,
2001; Benjamin, 2001).
Recently a viral sequence, tentatively termed V9, was
cloned from a patient with TAC that showed 11–14%
variability from the published B19 sequences (Nguyen
et al., 1998, 1999). The complete coding region of V9
was cloned and sequenced (GenBank Accession No.
AJ249437) and compared to the B19 genome. The region
of overlap between the two open reading frames encod-
ing the nonstructural protein (NS) and the putative 7.5-
kDa protein (Fig. 1) was relatively conserved between
B19 and V9, allowing the design of the NS1/7.5 erythro-
virus consensus PCR assay where primers encompass
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374an MunI (or its isoschizomer MfeI) restriction enzyme
site that would distinguish between B19- and V9-like
sequences (Nguyen, unpublished observations; Auguste
et al., 1999). This novel DNA assay was therefore em-
ployed to determine the prevalence of variant parvovi-
ruses in samples submitted to the Hematology Branch at
the National Institutes of Health (NIH) and in plasma
pools from Danish volunteer blood donors.
RESULTS
Cross hybridization of V9 and B19 plasmids
All serum and plasma samples submitted to the He-
matology Branch for B19 testing are routinely initially
tested by B19 dot blot hybridization. We therefore deter-
mined whether the B19 dot blot hybridization assay uti-
lized since 1990 would have detected the V9 sequence
or whether our assay would have missed these variants.
When diluted samples of V9 plasmid were hybridized
with the V9 probe, there was a detection limit of 10 pg.
The standard B19 dot blot probe could detect 100 pg of
both B19 and V9, although the signal was weaker for the
V9 sequences (data not shown). Hence, the results indi-
cated that our standard B19 dot blot would detect variant
sequences if 100 pg/10 L were present, equivalent to
2  109 genome copies/mL.
Results of testing samples for V9 by the NS1/7.5EC
PCRthe true clinical significance remains unknown. Current PCR
specific primers to the A6/V9/B19 common sequences. © 2
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When the NS1/7.5 EC PCR was tested using plasmids
containing the B19 (pYT103) or V9 (V9-C22) sequence theanalyse
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assay could routinely detect 20 copies of either virus/
reaction mix (Fig. 2). All sera and plasma samples (n 
149) submitted to the Hematology Branch for B19 testing
between 1998 and 2001 were tested by the NS1/7.5EC
PCR and 29 samples were positive. Of these 29 samples,
only 1 did not have the expectedMfeI restriction site and
sequencing of the amplicons indicated that all the se-
quences were parvovirus (Table 1). In addition, no atyp-
ical B19 sequences were detected in 18 bone marrow
samples submitted.
When DNA was extracted from 62 plasma pools from
Danish blood donors and tested by the NS1/7.5 EC PCR,
40 samples (65%) were positive. Of these 40 samples, all
PCR products were cut by MfeI digestion.
As the B19 dot blot hybridization would detect V9
sequences, we tested all B19 dot blot positive or equiv-
ocal samples sent to the laboratory between 1991 and
1998. Of the 58 samples tested, only 1 sample, coded A6,
contained an atypical B19 sequence. This sample was
submitted for testing in 1991 from an Italian HIV-positive
patient with chronic anemia. By dot blot assay using the
B19 probe there was an estimated viral titer of 1010
genome copies/mL (Fig. 3). Low levels of B19 antibody
(IgM, 1 au/mL (negative); IgG, 1.0 au/mL (equivocal))
were detectable in the A6 serum by radioimmunoassay.
The A6 sample was also tested by standard B19
PCR using both the L/M and the I/F sets of B19 primers.
Direct sequencing of the outside amplified product with
the I primer disclosed an atypical B19 sequence only
(90% divergence from B19-Au sequence, GenBank ID
M13178); no readable sequence was obtained with the F
primer.
Cloning of A6 and characterization
Using the primer based on the hairpin sequence of
B19 a 4844-nucleotide sequence (excluding the primer)
containing the entire coding region was cloned. Two
clones were chosen, completely sequenced, and com-
pared to the entire coding sequence of V9 and B19
FIG. 1. Genome map of parvovirus B19, indicating the positions of the
open reading frames, viral transcripts, and PCR primers used in this
paper. The transcript map is based on the data in the literature (Ozawa
et al., 1987b; Luo and Astell, 1993).
FIG. 2. Sensitivity of the NS1/7.5 EC PCR to detect B19, V9, and A6
sequences. Serial dilutions of plasmids containing B19 (pYT103), V9
(V9-C22) and A6 (A6-c8) were amplified with primers E1905F and
E1987R and the products were visualized by ethidium bromide staining
of a 2% agarose gel.
TABLE 1
Summary of the Results of Testing Samples by NS1/7.5EC PCR,
Restriction Enzyme Digestion of the PCR Products with MfeI, and
Sequencing the Amplicon
Samples tested
#
Tested
NS1/7.5 EC
PCR  ve
No
MfeI
site
Not
B19-like
sequence
Serum samples
(1998–2001)
149 29 1 0
Bone marrow (1998–2001) 18 4 0 0
B19 dotblot pos or
equivocal (1991–1998)
58 53 2 1
Plasma pools (2,000
donors each)
62 40 0 0
FIG. 3. Cross hybridization of A6 by standard parvovirus B19 dot blot
hybridization. Dot blots of serial dilutions of B19 (from plasmid pYT103)
and 10 L of A6 sera were hybridized with a B19-P32-labeled probe.
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isolates. The two clones (GenBank ID AY064475 and
AY064476) were 99.7% identical to each other. Compari-
son of the full A6 sequence with nucleic acid sequences
in GenBank confirmed homology with other members of
the parvovirus family, with highest homology to B19. The
A6 isolate exhibited 87.8% similarity to B19 (B19-Au se-
quence) and 92.0% to V9, compared to 98% correspon-
dence between reported B19 isolates and 86.6% similar-
ity between B19 and V9. A6 appeared to have the same
genomic organization as B19, with the two large open
reading frames and two smaller open reading frames
(Fig. 1) conserved ATG start and stop codons, splice
acceptor and donator sites, and transcription factors SP1
and YY1 binding sequences upstream of the promoter
region (Blundell and Astell, 1989; Momoeda et al., 1994).
The putative nonstructural protein (NS, nt 235–2250) has
671 amino acids (as B19) with 94.2% homology at the
amino acid level to B19 (Fig. 4A). The putative capsid
protein (nt 2243–4588) displayed 96.7% homology at the
amino acid level to B19 (Fig. 4B), with most of the varia-
tion—only 93.8% similarity—in the VP1 unique region
(aa 1–226).
Lack of infectivity of A6 in UT7/Epo/S1 cells
Only a limited amount of the serum was available,
excluding the possibility of performing erythroid progen-
itor inhibition studies (Mortimer et al., 1983). An RT-PCR
to detect the spliced viral transcripts of B19 has been
described to detect infectious B19 infection in UT7/Epo
cells (Bostic et al., 1999), and we developed a similar
assay to detect the spliced transcripts of A6, employing
a B19-permissive subclone of UT7/Epo, UT7/Epo/S1. Us-
ing dilutions of a B19-containing serum containing 2 
1013 genome copies/mL, our detection limit for B19 was
2 104 genome copies/well (Fig. 5). In contrast we could
not detect A6 transcripts, even at the lowest dilution of
serum (final dilution 102; or 107 genome copies/well). In
the absence of DNAse treatment, the primers amplified
nonspliced DNA indicating that the primers could bind
and amplify A6 sequence.
DISCUSSION
Since the original sequencing of B19 (Shade et al.,
1986) a large number of isolates have been sequenced
entirely, or in part, and multiple alignment studies indi-
cate that the sequence is well conserved, with 2%
divergence among full-length sequences. In addition,
studies to detect a correlation of specific disease pre-
sentation to B19 sequence genotype have been unsuc-
cessful, although there have been suggestions that there
is more sequence variation detected in patients with
persistent B19 infection (Hemauer et al., 1996). In addi-
tion, most of the variation has been located in the VP1
unique region, a region known to be important in the
development of neutralizing antibodies (Anderson et al.,
1995), while the NS protein is relatively conserved (Erd-
man et al., 1996; Hemauer et al., 1996). Even in the VP1
unique region, however, the variation has been 6.6%
(Gallinella et al., 1995; Haseyama et al., 1998; Nguyen et
al., 1999; Dorsch et al., 2001).
In 1998 the identification of an Erythrovirus isolate with
11% variation from B19-Au in a region including the VP1
unique region was reported (Nguyen et al., 1999). Retro-
spective studies also identified other partial sequences
with 10% variation from the B19 sequence (Nguyen,
unpublished observations; erythrovirus VX, GenBank Ac-
cession Nos. AJ249421, AJ249434). However, a Danish
study (Heegaard et al., 2001) failed to detect V9 se-
quence in 100 samples from B19 IgM positive individuals
or 50 plasma pools (from 100,000 blood donors) using
V9-specific primers based in the capsid region of the
virus. In the present study using a PCR based on the NS
region, we also did not detect any V9 sequence in serum
or plasma samples sent to NIH or in any of the Danish
plasma pools. However, we did identify, clone, and se-
quence a second atypical B19 sequence, distinct from
both V9 and B19 isolates. In addition, since completing
our studies a Finnish group has submitted to GenBank
an erythroviral sequence with 98% similarity to A6 (Gen-
Bank Accession No. AY044266). Thus, although these
variants are clearly present, the prevalence of these
viruses, although probably low, is unknown.
It has been suggested that these variants may not
have been detected before, due to the increasing reli-
ance on PCR-based techniques to detect B19 infection
(Nguyen et al., 1999). Our studies indicate that, although
obviously less sensitive than PCR, a standard B19 dot
blot hybridization would detect both V9 and A6 isolates,
provided that the titer was greater than 2  109 genome
copies/mL. This hybridization technique also permitted
detection of the more diverse and then unknown simian
parvovirus in anemic macaques (O’Sullivan et al., 1994;
Brown et al., 1995).
Similarly, although our standard B19 PCR did detect
the A6 sequence, the variation, especially in the non-
structural protein region, suggests that many other pub-
lished B19 primers will not work. Within the past 2 years
our laboratory has detected three sera with high titer B19
by our dot blot hybridization assay in samples previously
reported by other laboratories as B19 negative by PCR-
based assay. (All three samples were confirmed as con-
taining B19 sequences by sequence analysis.) This ap-
parent inability to detect high titers of B19 is particularly
relevant with the increased use of NAT testing to screen
blood and blood products for parvovirus contamination.
Obviously, B19 dot blot (sensitivity of 2  107 genome
copies/10 L) is less sensitive than PCR (sensitivity of
20 genome copies/10 L), and the new NS1/7.5EC PCR
which was designed specifically to effectively amplify
B19 and V9 (Nguyen QT unpublished observations; Au-
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FIG. 4. Alignment of the (A) nonstructural proteins and (B) capsid proteins of parvovirus B19, V9, and A6. Amino acids that are identical to those
in B19-Au are indicated with a period. Numbers are the nucleotide position: B19, GenBank M13178; V9_c22-1, GenBank AJ249437; A6-c2, GenBank
AY064475; A6-c8, GenBank AY064476. The box indicates the putative start of the VP2 capsid protein.
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guste et al., 1999) is capable of amplifying the new A6
variant also (Fig. 3). In addition B19/V9/A6 typing can be
performed by either MfeI restriction or sequencing of the
NS1/7.5EC PCR product, making this a very valuable tool
in detecting these new variants.
The clinical relevance of A6 and other B19 variants is
unknown. The inability to culture the virus could indicate
that this is a noninfectious mutant, but more likely infec-
tivity could have been lost in storage, heat-inactivation
(the serum was from an HIV-infected individual and,
although not documented, may well have been heat-
inactivated before it was sent to NIH), or the presence of
neutralizing antibodies. Alternatively, the virus may have
a different splicing pattern. Finally, A6 may have a differ-
ent tissue tropism and not infect erythroid progenitors,
analogous to the different tropisms of different strains of
the murine parvovirus, MVM, despite limited nucleotide
differences (Sahli et al., 1985; Astell et al., 1986), espe-
cially given the cluster of differences in the nonstructural
protein sequence. However, the clinical presentation of
anemia in an HIV-positive individual is against this. Fur-
ther studies are required to determine the prevalence of
B19 variants and their clinical significance.
MATERIALS AND METHODS
Plasmids, serum samples, and plasma pools
Dr. P. Tattersall kindly provided the plasmid pYT103
containing the entire coding region of the B19-Au isolate.
A plasmid, V9-C22, containing the complete coding se-
quence of V9 was obtained from Collection National de
Culture de Microorganisms (Institute Pasteur, Paris,
France: CNCM1-2066; GenBank Sequence AJ249437).
Serum samples were submitted to the Hematology
Branch specifically for testing for parvovirus B19 be-
tween 1991 and 2001. Samples were stored at 30 or
80°C until tested. In addition, 62 plasma pools each
derived from plasma from 2000 Danish voluntary blood
donors were tested. Fifty of these pools had previously
been tested for V9 using primers based in the capsid
coding region of the V9 sequence (Heegaard et al., 2001).
B19 and V9 dot blot hybridization
B19 DNA dot blot hybridization was performed as
previously described (Ozawa et al., 1987a). Briefly, plas-
mids pYT103 and V9-C22 were diluted to give a range of
DNA concentrations (0, 0.1, 1, 10, and 100 pg/l). For each
plasmid dilution, 10 l was added to 200 l 0.333 M
NaOH and incubated at room temperature to denature
the DNA. The samples were then applied to a nylon
membrane (0.45-m pore, Nytran Plus, Schleicher and
Schuell, Keene, NH) using a dot blot manifold apparatus
(96 well, Schleicher and Schuell), and the membrane
was washed in 6 SSC and baked at 80°C for an hour
in a vacuum oven. The membranes were hybridized with
a 32P-random-primed probe of the complete B19 coding
region (EcoRI digest of pYT103) or the complete V9
coding region (BamHI and EcoRI double digest of V9-
C22) in Hybrisol (Oncor, Inc.; 42°C overnight). The mem-
branes were washed with 2 SSC, 0.1% SDS at room
temperature and 0.1 SSC, 0.1% SDS for 20 min at 55°C
FIG. 5. Inability to detect spliced RNA transcripts in UT7/Epo/S1 cells infected with different concentrations of A6 sera. Sera containing 1010
genome copies/ml A6 or 2  1013 genome copies/ml of B19 were diluted and cultured in microtiter plate wells containing UT7/Epo/S1 cells in
quintuplicate (final volume 100 L). Cells were harvested on day 3 and RNA extracted, and RT-PCR for A6 or B19 was performed. To ensure that the
A6 primers were functional and would amplify the A6 sequence, dilutions of A6-c2 plasmid (5 L) were tested by PCR to demonstrate that the A6
primers could amplify nonspliced A6 DNA. (A) A6 RT-PCR (lanes 1–3) and A6 PCR (lanes 5–12). Spliced A6 products (282 and 162 bp) were not
detected even at the dilution of 102 (107 genome copies/well), although the primers could amplify A6 DNA (sensitivity of 104 ng/L; 105 genome
copies/PCR reaction). (B) B19 RT-PCR (lanes 1–6). In contrast to the A6 RT-PCR results, B19 products (253 and 133 bp) could be detected at a dilution
of 108, or 2  104 genome copies/well. Bl indicates a blank line.
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and then exposed to either a PhosphoImager cassette
(Molecular Dynamics) or an X-ray film.
For serum samples, 10 l was denatured with NaOH
and analyzed as above, using the B19 DNA probe for
detection of parvovirus DNA.
B19 and NS1/7.5EC PCR
DNA was extracted from serum or plasma (50 or 200
L), plasma pools (200 L), or bone marrow (5  106
cells) using the DNAEAsy method (Qiagen, Inc., Valencia,
CA) and tested for B19 by nested polymerase chain
reaction as previously described (Clewley, 1993). Specif-
ically, the primary round (30 cycles) of PCR was per-
formed using 30 pmol of primers L (nt 1419–1435; (Shade
et al., 1986)) and M (nt 2139–2123) in a 50-L volume with
ExTaq DNA polymerase (Panvera Corp., Madison, WI),
and 5 L of the product was reamplified using primer
pair F (nt 1498–1520) and I (nt 2088–2065). Confirmation
of the specificity of the PCR product was performed by
Southern hybridization using a probe of the product of
PCR amplication of pYT103 with primer pair J (nt 1629–
1650) and K (nt 1979–1958) labeled either by 32P-nick-
translation or alkaline phosphatase (Alkphos Direct La-
beling with CDPStar kit; Amersham Pharmacia Biotech,
Inc., Piscataway, NJ).
NS1/7.5EC PCR was performed using primer set B
(Auguste et al., 1999), which is common to both parvovi-
rus B19 and V9. Specifically, PCR was performed using
12.5 pmol of primers E1905F (nt 1905–1923) and E1987R
(nt 2007–1987) in a 50-l volume using AmpliTaq Gold
(Perkin–Elmer) with 50 cycles of amplification (94°C, 6
min; 5 cycles of 94°C, 30 s; 55°C, 1 min; 72°C, 1 min;
then 45 cycles of 94°C, 30 s; 60°C, 30 s; 72°C, 30 s;
followed by 72°C extension for 7 min). Confirmation of
the specificity of the PCR product was performed by
Southern hybridization using an alkaline-phosphatase-
labeled oligonucleotide, E1954P (nt 1954–1989).
To distinguish between B19 and putative V9 se-
quences, the V9 PCR product (10 L) was incubated
directly with MfeI restriction enzyme for 2 h prior to the
products being run on a 2.5% agarose gel (either 3:1
Nusieve or Seakem GTG agarose, BioWhittaker, Rock-
land, ME). In addition, the sequence of the PCR product
was determined, by either direct sequencing of the am-
plicon after purification (Qiaquick PCR purification kit,
Qiagen, Inc.) using BigDye terminator cycle sequencing
(Applied Biosystems, Foster City, CA) or by TA cloning of
the PCR product into PCR2.1 TOPO (Invitrogen, Carlsbad,
CA), transformation of Top10 cells (Invitrogen), and se-
quencing of the resultant plasmids.
B19 antibody testing
B19 parvovirus-specific antibodies were tested by im-
munocapture radioimmunoassay (Cohen et al., 1983).
Cloning and sequencing of A6
Amplification of the full-coding length of A6 was per-
formed using a primer based in the common repeated
sequence in both the 5 and the 3 hairpin regions of
parvovirus B19 and V9. DNA extracted from serum A6
was amplified with primer EC 173FR (nt 174–192 with an
additional EcoRI site at the 5 end; ccg-aat-tca-tct-gat-
ttg-gtg-tct-tc) and a high-fidelity DNA polymerase (HF-2
kit using 0% ADV2 buffer, Clontech, Palo Alto, CA) using
25 cycles of amplification (94°C, 15 s; 55°C, 30 s; 72°C,
4 min; followed by 72°C extension for 7 min). The ampli-
fied product was cloned by blunt ligation into a pCR-
Blunt II TOPO (Invitrogen) and transformed into Top10
cells (Invitrogen).
Plasmids containing the full-length sequence were
sequenced in both directions using the BigDye termina-
tor sequencing kit (Applied Biosystems). All sequences
obtained, and the amino acid sequence of the open
reading frames, were analyzed using Lasergene soft-
ware (DNAStar, Inc., Madison, WI): DNA pairwise homol-
ogy was determined by the Wilbur–Lipman method, with
a gap penalty of 3 and deletion penalty of 3; amino acid
pairwise homology was determined by the Lipman–Pear-
son method with a Ktuple of 2, gap penalty of 4, and
deletion penalty of 12; multiple sequence alignments
were determined using the Megalign program, using the
Clustal method with a gap penalty of 10 and gap length
penalty of 10.
RT-PCR of infectivity
Based on the genome similarity to B19 and the se-
quence of A6, an RT-PCR for A6 viral capsid transcripts
was developed and used to test for A6 infectivity of
UT7/Epo/S1 cells (Morita et al., 2001), a subclone of the
UT7/Epo cell line previously shown to be permissive for
B19 (Shimomura et al., 1992). UT7/Epo/S1 cells, a kind
gift of Dr. Morita, were maintained in Iscove’s modified
DMEM with 10% fetal calf serum and 2 U/mL of erythro-
poietin. Infections were performed in 96-well microtiter
plates. Cells (10 L at 2  106 cells/mL) were incubated
with an equal volume of diluted serum for 2 h at 4°C to
allow viral binding to cells. Following attachment, cells
were diluted to a final density of 2  105 cells/mL (in a
volume of 100 L) and incubated at 37°C for 3 days
before being harvested by centrifugation. RNA was ex-
tracted from 105 cells with RNA Stat 60 (TelTest,
Friendswood, TX) with 5 g of tRNA as carrier and
dissolved in 10 L of H2O. Residual DNA was removed
by DNAse I treatment (final concentration, 90 U/mL) for
15 min, prior to cDNA synthesis with random hexamers
and Superscript II reverse transcriptase (Life Technolo-
gies, Gaithersburg, MD). Amplification of the spliced
product of B19 involved primers B19-9 (nt 384–402) and
B19-1 (nt 2139–2120) using the same amplification con-
ditions as for B19 PCR. Similarly, amplification of the
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spliced product of A6 was using primers designed from
the A6 sequence A6-9 (ttt-gcc-tgc-taa-tta-aca) and A6-1
(act-ggt-ctg-caa-gtg-gag-tg). (In order to design primers
with suitable Tm and stability the position of the A6
primers was in a similar, but not identical, region of the
genome, with a predicted splice product 29 nt larger than
the B19 amplicon.) All products were analyzed by aga-
rose gel electrophoresis and Southern blotting of the
products with an alkaline-phosphatase-labeled probe
(B19, nt 2103–2138; A6, cca-gtt-tcc-tcc-gaa-gtg-gta-gcc-
gcg-tcg-tgg-gag). Extraction, integrity of RNA, and cDNA
synthesis in all samples were tested and confirmed by
detection of GAPDH transcripts (GenBank XM_033269,
nt 101–312).
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